4.3 Review

Osteoclast differentiation by RANKL and OPG signaling pathways

Journal

JOURNAL OF BONE AND MINERAL METABOLISM
Volume 39, Issue 1, Pages 19-26

Publisher

SPRINGER JAPAN KK
DOI: 10.1007/s00774-020-01162-6

Keywords

Osteoclast; Osteoblast; Bone resorption; RANKL; OPG

Funding

  1. JSPS KAKENHI [19K10395, 17K19776, 16H05508, 16K11818, 15K11377, 15K15688]
  2. Grants-in-Aid for Scientific Research [15K11377, 15K15688, 16H05508, 19K10395, 16K11818, 17K19776] Funding Source: KAKEN

Ask authors/readers for more resources

Osteoclasts and osteoblasts play essential roles in bone remodeling, with the regulation of RANKL and OPG expression being a key mechanism. The balance between these factors is crucial for maintaining bone density and preventing bone loss.
Introduction In bone tissue, bone resorption by osteoclasts and bone formation by osteoblasts are repeated continuously. Osteoclasts are multinucleated cells that derive from monocyte-/macrophage-lineage cells and resorb bone. In contrast, osteoblasts mediate osteoclastogenesis by expressing receptor activator of nuclear factor-kappa B ligand (RANKL), which is expressed as a membrane-associated cytokine. Osteoprotegerin (OPG) is a soluble RANKL decoy receptor that is predominantly produced by osteoblasts and which prevents osteoclast formation and osteoclastic bone resorption by inhibiting the RANKL-RANKL receptor interaction. Materials and Methods In this review, we would like to summarize our experimental results on signal transduction that regulates the expression of RANKL and OPG. Results Using OPG gene-deficient mice, we have demonstrated that OPG and sclerostin produced by osteocytes play an important role in the maintenance of cortical and alveolar bone. In addition, it was shown that osteoclast-derived leukemia inhibitory factor (LIF) reduces the expression of sclerostin in osteocytes and promotes bone formation. WP9QY (W9) is a peptide that was designed to be structurally similar to one of the cysteine-rich TNF-receptortype-I domains. Addition of the W9 peptide to bone marrow culture simultaneously inhibited osteoclast differentiation and stimulated osteoblastic cell proliferation. An anti-sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) antibody inhibited multinucleated osteoclast formation induced by RANKL and macrophage colony-stimulating factor (M-CSF). Pit-forming activity of osteoclasts was also inhibited by the anti-Siglec-15 antibody. In addition, anti-Siglec-15 antibody treatment stimulated the appearance of osteoblasts in cultures of mouse bone marrow cells in the presence of RANKL and M-CSF. Conclusions Bone mass loss depends on the RANK-RANKL-OPG system, which is a major regulatory system of osteoclast differentiation induction, activation, and survival.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available